TOKYO, Jan 31 (Reuters) – Japanese trading and pharmaceutical company Kowa Co Ltd (7807.T) said on Monday anti-parasite drug ivermectin has an “antiviral effect” against Omicron and other variants of COVID-19 as Phase III clinical trials continue.
The company did not provide further details.
The firm has been working with Kitasato University, a medical university in Tokyo, on testing the drug which is used to treat parasites in animals and humans, as a potential treatment for COVID-19.
Clinical trials are ongoing but promotion of the drug as a COVID-19 treatment has generated controversy.
The drug is not approved for treatment of COVID-19 in Japan and the U.S. Federal Drug Administration, the World Health Organization and the EU drug regulator have warned against its use.
Register now for FREE unlimited access to Reuters.com
Reporting by Sam Nussey and Rocky Swift;
Editing by Tomasz Janowskiand Louise Heavens
Our Standards: The Thomson Reuters Trust Principles.